Followers | 149 |
Posts | 17898 |
Boards Moderated | 0 |
Alias Born | 04/12/2012 |
Tuesday, March 13, 2018 9:35:27 PM
MT NEWSWIRES 2:19 PM ET 3/13/2018
04:19 PM EDT, 03/13/2018 (MT Newswires) -- ImmunoCellular Therapeutics'(IMUC/WS) net loss narrowed sharply to $0.01 per share in Q4 from $1.36 per share a year earlier, helped by the suspension of its late-stage trial of ICT-107.
It had no revenue as it is still developing immune-based therapies for cancer.
Price: 0.3333, Change: +0.02, Percent Change: +5.78
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
©http://www.mtnewswires.com Copyright © 2018 MT Newswires
Recent IMUC News
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 08/02/2023 07:11:57 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM